Development of novel arginase inhibitors for therapy of endothelial dysfunction
about
Arginase as a Critical Prooxidant Mediator in the Binomial Endothelial Dysfunction-AtherosclerosisArginase inhibition enhances angiogenesis in endothelial cells exposed to hypoxia.Expression of arginase I and inducible nitric oxide synthase in the peripheral blood and lymph nodes of HIV‑positive patients.Deregulation of arginase induces bone complications in high-fat/high-sucrose diet diabetic mouse modelProtective Role of Arginase II in Cerebral Ischemia and Excitotoxicity.Arginase: an old enzyme with new tricks.Pharmacokinetics and Pharmacodynamics of Promising Arginase Inhibitors.Central Role of Metabolism in Endothelial Cell Function and Vascular Disease.Arginase inhibition prevents bleomycin-induced pulmonary hypertension, vascular remodeling, and collagen deposition in neonatal rat lungs.Topiramate ameliorates abdominal aorta cross-clamping induced liver injury in rats.Arginase in the vascular endothelium: friend or foe?Ablation of Arginase II Spares Arginine and Abolishes the Arginine Requirement for Growth in Male Mice.Vascular surgical stretch injury leads to activation of P2X7 receptors and impaired endothelial function.Endothelial Gab1 deficiency aggravates splenomegaly in portal hypertension independent of angiogenesis.Trypanosomatid Infections: How Do Parasites and Their Excreted-Secreted Factors Modulate the Inducible Metabolism of l-Arginine in Macrophages?The Essential Element Manganese, Oxidative Stress, and Metabolic Diseases: Links and Interactions.The Involvement of Arginase and Nitric Oxide Synthase in Breast Cancer Development: Arginase and NO Synthase as Therapeutic Targets in Cancer.Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis.
P2860
Q26991946-AF749B0B-A91D-4679-B8B4-2546B5434B44Q35181215-1448D0A9-92DA-4C5F-8BC9-E58416D4D592Q36390189-BB01BB65-9D63-4EE1-9808-6D8D02B4B0ECQ36775423-3CE8FDE9-B7F8-4ADA-859F-40B2D12D264CQ36998882-084D3802-67E4-422B-A83B-F9C8CEBF8601Q38452432-446615F0-1DC9-4B78-9240-D6A2EF0831ADQ38979298-6E4DF1BA-2B0A-4A45-9870-788131687D24Q39137289-829D8981-536A-4D71-B58A-37B82152B421Q41572196-B45C2077-965F-41C3-B294-01F8283A77EBQ42943492-5EA684D0-262C-4500-A0D7-A9F39B3B41C0Q43007746-5C19A840-E889-4F39-984B-C1D9E360E30EQ46340278-F93F9FFE-2634-4D37-9E53-C0242A9524D7Q46856693-8965B2D9-B6AC-4381-B004-DC1914003E30Q48246000-95EAD961-7056-4EF7-8928-A364FA5D9786Q53685684-9D55CDB1-D009-459E-AF02-75E3F1B3C735Q55176253-F119E0E8-414A-4C47-958C-832FD4631BCCQ55264413-07769EE3-6ED2-4E6B-8738-EEAC4E060920Q55476883-725D1CEC-38C3-40A9-A3A1-03D4517F7248
P2860
Development of novel arginase inhibitors for therapy of endothelial dysfunction
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of novel arginase inhibitors for therapy of endothelial dysfunction
@en
Development of novel arginase inhibitors for therapy of endothelial dysfunction.
@nl
type
label
Development of novel arginase inhibitors for therapy of endothelial dysfunction
@en
Development of novel arginase inhibitors for therapy of endothelial dysfunction.
@nl
prefLabel
Development of novel arginase inhibitors for therapy of endothelial dysfunction
@en
Development of novel arginase inhibitors for therapy of endothelial dysfunction.
@nl
P2093
P2860
P356
P1476
Development of novel arginase inhibitors for therapy of endothelial dysfunction
@en
P2093
Dan E Berkowitz
Daniel Nyhan
Jochen Steppan
P2860
P356
10.3389/FIMMU.2013.00278
P577
2013-09-17T00:00:00Z